As expected, Vivus (VVUS) got FDA approval for its anti-obesity drug Qsymia (formerly known as Qnexa) on Tuesday. With both Arena Pharmaceuticals (ARNA)
and Vivus beating the odds and getting the FDA go-ahead, the race is
now on to disprove the skeptics (and validate the bulls) and rack up
significant prescriptions and drug sales. While I do believe Vivus has
the edge in this race, investors should not underestimate the challenges
of launching new drugs to skeptical docs.
Please read more here:
With Qsymia Approval, The Race Is Now On
No comments:
Post a Comment